Picture this: an HR director at a mid-sized manufacturing company reviews the renewal package. The pharmacy line is up 18%. The carrier flags GLP-1 medications as the primary driver. The company added GLP-1 coverage for weight management eighteen months ago because employees asked for it, and because the benefits consultant said it was becoming standard. Nobody designed a clinical access strategy. Nobody integrated it with the wellness program. Nobody established success metrics. The coverage was added as a benefit feature, not as part of a population health strategy. The cost showed up. The outcomes did not.
This scenario is playing out across the mid-market. GLP-1 medications now account for approximately 14% of all US prescription drug spending in 2026, according to HFMA. Among employers who added coverage without a structured clinical framework, the cost trajectory has been difficult to justify at renewal. Among employers who integrated GLP-1 coverage into a comprehensive wellness strategy, the data looks materially different.
Why Coverage Without Strategy Produces the Wrong Outcome
GLP-1 medications are clinically effective. The evidence on weight reduction, glycemic control, cardiovascular risk reduction, and kidney health outcomes is robust and expanding. The problem is not the drug. The problem is that a prescription benefit, in isolation, does not produce population health outcomes. It produces prescription fills.
Obesity contributes to more than 60 chronic conditions and results in 66% higher annual healthcare costs for affected individuals, according to research cited by SHRM. Addressing obesity at the population level, which GLP-1 coverage theoretically enables, requires sustained clinical support, behavioral change infrastructure, and ongoing monitoring. An employee who fills an Ozempic prescription but has no access to nutritional counseling, no integration with a weight management program, and no clinical follow-up is likely to discontinue the medication within six months. The research on GLP-1 discontinuation rates is consistent: without structured support, most patients stop taking the medication before reaching clinically meaningful outcomes, and the costs of the prescriptions they did fill generate no long-term savings.
What a GLP-1 Wellness Strategy Actually Requires
The employers producing favorable GLP-1 outcomes have built three things that employers who simply added the pharmacy benefit have not.
Clinical access criteria tied to population health goals: Access to GLP-1 coverage for weight management should be tied to documented clinical criteria, BMI thresholds, comorbidity presence, or a combination, rather than open to any employee who requests a prescription. Clinical criteria serve two purposes: they direct coverage to the employees most likely to benefit from GLP-1 therapy and least likely to discontinue, and they reduce the actuarial cost of the benefit by focusing utilization on the highest-need population. A well-designed access policy also requires initial evaluation by a primary care physician or endocrinologist, establishing the clinical relationship that ongoing monitoring depends on.
Integration with a weight management and disease management program: A GLP-1 prescription without behavioral support is a pharmacological intervention without the behavioral change infrastructure that determines whether weight loss is sustained. Employers who have integrated GLP-1 coverage with structured weight management programs, including nutritional counseling, activity goals, and regular clinical check-ins, report significantly better adherence rates and outcomes than those who offered the drug as a standalone pharmacy benefit. The population health management services at Tooher-Ferraris help employers design and deploy these support structures as a coordinated extension of the health plan, not as a separate wellness program that competes with it.
PBM contract alignment and rebate optimization: GLP-1 medications carry significant list prices. Brand-name drugs approved for weight management can cost more than $1,000 per month per patient without rebates or negotiated discounts. The net cost to the employer is substantially determined by PBM contract terms: rebate pass-through rates, formulary positioning of specific agents, and step therapy requirements that prioritize lower-cost alternatives within the therapeutic class where clinically appropriate. Employers whose PBM contracts were written before GLP-1 medications represented a significant portion of pharmacy spend may be operating under terms that do not reflect current market dynamics for this drug class.

How to Measure Whether the Investment Is Working
A renewal discussion about GLP-1 coverage should include more than pharmacy spending. Employers can use three measures to assess costs, access and outcomes over time.
1. Total cost of care. Combine medical and pharmacy claims to track spending for members using GLP-1 medications over rolling 12-month periods. Compare results with their own costs before treatment and, where feasible, with a group that has similar health characteristics. A simple comparison with all non-users can be misleading because the groups may have different health needs at the outset.
2. Relevant health outcomes. Work with clinical and analytics partners to select measures that fit the population and the medication’s approved use. Changes in weight, blood pressure or other appropriate clinical measures may be useful when reliable data is available. A change in diagnosis counts alone does not prove that treatment improved health or reduced costs.
3. Treatment continuation. Track how many members remain on treatment at set intervals and investigate why others stop. Side effects, affordability, access barriers and treatment response can all play a role; a high discontinuation rate does not automatically point to a lack of behavioral support. Research on GLP-1 discontinuation among patients with obesity identifies several such reasons. PMC
Tooher-Ferraris helps employers connect coverage decisions with wellness and population health management and pharmacy management. Bringing those services together can help employers define meaningful measures before the next renewal. Tooher-Ferraris
Ready to assess your GLP-1 strategy using both cost and outcome data? Contact Tooher-Ferraris to schedule a no-obligation consultation.
Frequently Asked Questions
Why does GLP-1 coverage cost more for some employers than others?
The cost difference is driven primarily by three factors: the breadth of access criteria (open access versus clinically restricted access), the presence or absence of integrated behavioral support programs that improve adherence and outcomes, and PBM contract terms that determine the net cost of the drug after rebates and discounts. Employers with narrow clinical criteria, strong support programs, and competitive PBM contracts consistently report lower per-member GLP-1 costs than those without these elements.
What clinical criteria should employers use for GLP-1 coverage?
Most employers tie GLP-1 coverage for weight management to a BMI threshold of 30 or above, or a BMI of 27 or above with a qualifying comorbidity such as type 2 diabetes, hypertension, or sleep apnea. Some employers also require documented failure of a structured diet and exercise program before approving GLP-1 therapy for weight management. These criteria align with FDA labeling and focus coverage on the population most likely to achieve clinically meaningful outcomes.
How do you measure the ROI of GLP-1 coverage in an employer health plan?
The most meaningful ROI metric is total cost of care trend for GLP-1 users compared to a matched control group of non-users, measured over 12 to 18 months. Aon’s research across 192,000 GLP-1 users found 3% medical cost growth versus 9% for a control group, a gap attributable to reduced utilization for obesity-related conditions. Employers who track only pharmacy costs see the cost side without the medical cost offset that represents the long-term value of the coverage.








